Intermediate-risk Non–muscle-invasive Bladder Cancer: Time To Tidy Up the Mess?
Authors:
- 27 July 2022
- journal article
- editorial
- Published by Elsevier in European Urology Oncology
- Vol. 5 (5) , 517-518
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer GroupEuropean Urology Oncology, 2022
- European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)European Urology, 2022
- Stratification of Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: Implications for Adjuvant TherapiesEuropean Urology Focus, 2021
- European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines PanelEuropean Urology, 2021
- Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2020
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelineJournal of Urology, 2016
- Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, 2002